Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers

The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein. BET protein alterations are associated with some solid tumor cancers, including...

Full description

Bibliographic Details
Main Authors:	Martin V. Nguyen, Lydia Loof, Gerald S. Falchook
Format:	Article
Language:	English
Published:	Innovative Healthcare Institute 2020-02-01
Series:	Journal of Immunotherapy and Precision Oncology
Subjects:	bromodomain and extraterminal domain bromodomain and extraterminal inhibitor cancer clinical trial review
Online Access:	https://jipo.org/doi/pdf/10.4103/JIPO.JIPO_2_20

Similar Items

BRD4: An emerging prospective therapeutic target in glioma
by: Hua Yang, et al.
Published: (2021-06-01)

BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin Cells
by: Jessica Sriha, et al.
Published: (2022-06-01)

Immunotherapy With Human Gamma Delta T Cells—Synergistic Potential of Epigenetic Drugs?
by: Jaydeep Bhat, et al.
Published: (2018-03-01)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
by: Noah R. Flynn, et al.
Published: (2021-06-01)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
by: Rosemarie Tremblay-LeMay, et al.
Published: (2018-03-01)

Quercetin Enhances the Anti-Tumor Effects of BET Inhibitors by Suppressing hnRNPA1
by: Thao N.D. Pham, et al.
Published: (2019-09-01)

Histone Acetylation and Modifiers in Renal Fibrosis
by: Fengchen Shen, et al.
Published: (2022-04-01)

Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma Cells
by: Yuki Kotani, et al.
Published: (2024-03-01)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
by: Jiacheng Lai, et al.
Published: (2021-09-01)

Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins
by: Ping Bai, et al.
Published: (2020-08-01)

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
by: Archit Trivedi, et al.
Published: (2020-03-01)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
by: Kenneth K. W. To, et al.
Published: (2023-03-01)

The Functions of BET Proteins in Gene Transcription of Biology and Diseases
by: Ka Lung Cheung, et al.
Published: (2021-09-01)

Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
by: Dayu Wu, et al.
Published: (2022-08-01)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
by: Elisa Funck-Brentano, et al.
Published: (2021-01-01)

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
by: Yanli Sun, et al.
Published: (2021-01-01)

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease
by: Katiri J. Snyder, et al.
Published: (2021-10-01)

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
by: Irawati Kandela, et al.
Published: (2015-06-01)

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
by: Fraser Aird, et al.
Published: (2017-01-01)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
by: Wendy Mao, et al.
Published: (2019-10-01)

Unveiling the folding mechanism of the Bromodomains
by: Maria Petrosino, et al.
Published: (2017-09-01)

BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT
by: Sabrina N. Copsel, et al.
Published: (2019-01-01)

The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
by: Ana S. Leal, et al.
Published: (2020-12-01)

CBP/p300 bromodomain: new promising epigenetic target
by: Xiang Qiuping, et al.
Published: (2022-01-01)

CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation
by: Veronica Garcia-Carpizo, et al.
Published: (2018-06-01)

The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
by: Chiara Tarantelli, et al.
Published: (2021-12-01)

Maintenance of muscle myosin levels in adult C. elegans requires both the double bromodomain protein BET-1 and sumoylation
by: Kate Fisher, et al.
Published: (2013-10-01)

N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
by: Joshua A. Nord, et al.
Published: (2022-09-01)

Genome-wide analysis of bromodomain gene family in Arabidopsis and rice
by: T. V. Abiraami, et al.
Published: (2023-03-01)

Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors
by: Siao Chen, et al.
Published: (2021-12-01)

Bromodomain inhibitors and cancer therapy: From structures to applications
by: Montserrat Pérez-Salvia, et al.
Published: (2017-05-01)

Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma
by: Yuting Meng, et al.
Published: (2021-04-01)

Pharmacological Modulation of BET Family in Sepsis
by: Nian Wang, et al.
Published: (2021-03-01)

The bromodomain-containing protein Ibd1 links multiple chromatin-related protein complexes to highly expressed genes in Tetrahymena thermophila
by: Alejandro Saettone, et al.
Published: (2018-03-01)

Bromodomain-containing factor GTE4 regulates Arabidopsis immune response
by: Qin Zhou, et al.
Published: (2022-11-01)

Bromodomain AAA+ ATPases get into shape
by: Magdalena Murawska, et al.
Published: (2020-01-01)

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial
by: John Hilton, et al.
Published: (2022-08-01)

The Bivalent Bromodomain Inhibitor MT-1 Inhibits Prostate Cancer Growth
by: Sanjeev Shukla, et al.
Published: (2023-07-01)

The emerging role of BET inhibitors in breast cancer
by: Angeliki Andrikopoulou, et al.
Published: (2020-10-01)

Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia
by: Juan José Fung, et al.
Published: (2015-09-01)